Atria Wealth Solutions Inc. decreased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 14,109 shares of the company's stock after selling 1,610 shares during the period. Atria Wealth Solutions Inc.'s holdings in Zoetis were worth $2,299,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its holdings in shares of Zoetis by 2.1% in the 4th quarter. Venturi Wealth Management LLC now owns 11,964 shares of the company's stock valued at $1,949,000 after buying an additional 250 shares during the period. Empower Advisory Group LLC grew its holdings in shares of Zoetis by 13.8% in the 4th quarter. Empower Advisory Group LLC now owns 1,761 shares of the company's stock valued at $287,000 after buying an additional 213 shares during the period. CIBC Asset Management Inc increased its holdings in Zoetis by 24.1% during the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company's stock worth $38,617,000 after purchasing an additional 46,050 shares in the last quarter. Sanctuary Advisors LLC lifted its holdings in shares of Zoetis by 0.9% in the fourth quarter. Sanctuary Advisors LLC now owns 106,189 shares of the company's stock valued at $18,340,000 after purchasing an additional 918 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Zoetis during the fourth quarter worth about $400,000. Institutional investors and hedge funds own 92.80% of the company's stock.
In other Zoetis news, EVP Roxanne Lagano sold 326 shares of the business's stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total value of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company's stock, valued at approximately $2,757,196.26. The trade was a 1.98 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.16% of the stock is currently owned by company insiders.
Shares of NYSE:ZTS traded up $2.97 during midday trading on Friday, hitting $160.39. 3,299,241 shares of the stock were exchanged, compared to its average volume of 3,434,359. The stock has a market capitalization of $71.82 billion, a price-to-earnings ratio of 29.32, a P/E/G ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The business's 50-day moving average price is $166.51 and its 200 day moving average price is $178.04. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53.
Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping the consensus estimate of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analysts' expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. Analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.25%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis's payout ratio is presently 36.56%.
Several equities analysts have recently weighed in on the stock. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a "neutral" rating and a $196.00 price target for the company. Morgan Stanley decreased their target price on shares of Zoetis from $243.00 to $238.00 and set an "overweight" rating for the company in a research note on Friday, February 14th. Stifel Nicolaus cut their price target on Zoetis from $210.00 to $180.00 and set a "buy" rating for the company in a report on Tuesday, January 7th. Leerink Partnrs raised Zoetis to a "strong-buy" rating in a report on Monday, December 2nd. Finally, Barclays boosted their price target on Zoetis from $242.00 to $244.00 and gave the company an "overweight" rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, nine have given a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $215.40.
Read Our Latest Research Report on ZTS
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Before you consider Zoetis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zoetis wasn't on the list.
While Zoetis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.